Adamas Pharmaceuticals Inc (OQ:ADMS)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 1900 Powell St Ste 1000
EMERYVILLE CA 94608-1839
Tel: N/A
IR: See website
Key People
David L. Mahoney
Lead Independent Chairman of the Board
Neil McFarlane
Chief Executive Officer, Director
Christopher B. Prentiss
Chief Financial Officer, Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer
Vijay Shreedhar
Chief Commercial Officer
Business Overview
Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).
Financial Overview
For the six months ended 30 June 2020, Adamas Pharmaceuticals Inc revenues increased 37% to $33.3M. Net loss decreased 50% to $27.2M. Revenues reflect Product sales increase of 33% to $32.4M. Lower net loss reflects Other Research and Development. decrease of 73% to $4.8M (expense), Other General and Administrative. decrease of 6% to $44.8M (expense), Stock-based Compensation in General and decrease of 43% to $3M (expense).
Employees: 136 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $160.74M as of Jun 30, 2020
Annual revenue (TTM): $63.56M as of Jun 30, 2020
EBITDA (TTM): -$63.22M as of Jun 30, 2020
Net annual income (TTM): -$77.87M as of Jun 30, 2020
Free cash flow (TTM): -$66.50M as of Jun 30, 2020
Net Debt Last Fiscal Year: $26.12M as of Jun 30, 2020
Shares outstanding: 28,281,840 as of Jul 31, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.